한글목차

세계의 중추신경계(CNS) 바이오마커 시장 규모는 2025년 76억 달러에서 2030년말에는 138억 달러에 달할 것으로 예측되고 있으며, 2025-2030년 CAGR은 12.6%로 전망되고 있습니다.

북미 시장은 2025년 27억 달러에서 2030년말에는 50억 달러에 달할 것으로 예측되고 있으며, 2025-2030년 CAGR은 13.4%로 전망되고 있습니다.

아시아태평양 시장은 2025년 17억 달러에서 2030년말에는 32억 달러에 달할 것으로 예측되고 있으며, 2025-2030년 CAGR은 14.1%로 전망되고 있습니다.

세계의 중추신경계(CNS) 바이오마커 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 동향, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약
• 시장 역학 및 성장 요인
• 신기술
• 부문 분석
• 지역 분석
• 결론

제2장 시장 개요

• 현재 시장 개요
• 전망
• 거시경제적 요인 분석
• 미국 관세가 시장에 미치는 영향
• 우크라이나-러시아 전쟁의 영향
• 세계 경제의 안정과 공급망
• 공공 및 민간 R&D 투자
• 의료비 지출과 경제 성장
• 고령화와 질병 부담
• Porter's Five Forces 분석

제3장 시장 역학

• 시장 역학 스냅샷
• 시장 성장 촉진요인
• 신경질환 유병률
• 진단 기술 및 연구 발전
• 조기 발견과 개인 맞춤형 의료에 집중
• 시장 성장 억제요인
• 고도의 진단 검사에 대한 높은 비용
• 규제 및 검증 과제
• 의료 서비스 제공업체의 인지도와 도입의 한계
• 시장 기회
• 신경퇴행성 질환 연구의 성장
• 조기 진단 및 검진 프로그램 확대
• 개인 맞춤형 의료와의 통합

제4장 규제 현황

• 규제 프레임워크
• 미국
• 유럽
• 인도
• 호주
• 일본

5장 신기술 및 특허 분석

• 개요
• 신기술
• 고해상도 질량 분석
• 차세대 시퀀싱
• 멀티플렉스 면역 측정
• 단일 세포 RNA 시퀀싱
• 특허 분석
• 주요 포인트
• 특허 : 연도별
• 특허 : 주요 관할권별
• 특허 : 출원인별

6장 시장 세분화 분석

• 세분화 내역
• 세계 CNS 바이오마커 시장 : 질환별
• 주요 포인트
• 알츠하이머병
• MS,ALS,FTD
• 파킨슨병
• 기타
• 세계 CNS 바이오마커 시장 : 용도별
• 주요 포인트
• 의약품 발견 및 개발
• 임상 진단
• 개인 맞춤형 의료
• 세계 CNS 바이오마커 시장 : 기술별
• 주요 포인트
• 단백질체학
• 분자 이미징
• 유전체학
• 세계 CNS 바이오마커 시장 : 바이오마커 유형별 시장 현황
• 주요 포인트
• 아밀로이드 베타
• 타우 단백질
• 기타
• 지리적 분류
• 세계 CNS 바이오마커 시장 : 지역별
• 주요 포인트
• 북미
• 유럽
• 아시아태평양
• 중동 및 아프리카
• 남미

제7장 경쟁정보

• 산업 구조
• 기업의 시장 점유율 분석
• 전략 분석

8장 중추신경계(CNS) 바이오마커 시장의 지속가능성: ESG 관점

• ESG: 소개
• CNS 바이오마커 산업의 지속가능성 동향 및 노력
• 결론

제9장 부록

• 조사방법
• 약어
• 기업 소개
• ABBOTT
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• C2N DIAGNOSTICS
• F. HOFFMANN-LA ROCHE LTD.
• FUJIREBIO
• LABCORP
• LILLY USA LLC.
• MERCK KGAA
• QUANTERIX
• QUEST DIAGNOSTICS INC.
• REVVITY
• SIEMENS HEALTHINEERS AG
• SYSMEX CORP.
• THERMO FISHER SCIENTIFIC INC.
• 신생 스타트업 기업, 시장 파괴자

영문목차

The global market for central nervous system (CNS) biomarkers is estimated to grow from $7.6 billion in 2025 to reach $13.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 through 2030.

The North American market for CNS biomarkers is estimated to grow from $2.7 billion in 2025 to reach $5 billion by the end of 2030, at a CAGR of 13.4% from 2025 through 2030.

The Asia-Pacific market for CNS biomarkers is estimated to grow from $1.7 billion in 2025 to reach $3.2 billion by the end of 2030, at a CAGR of 14.1% from 2025 through 2030.

Report Scope

The report examines and segments the global central nervous system (CNS) biomarkers market by disease, application, technology and biomarker type. It also provides insights into emerging trends and potential growth drivers. The report focuses on Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease and others. By application, it examines drug discovery and development, clinical diagnostics and personalized medicine. By technology, proteomics, molecular imaging and genomics are reviewed. Finally, biomarker types such as amyloid-beta, tau protein and others are considered.

The report also provides an inclusive regional analysis covering North America, Europe, Asia-Pacific, South America and the Middle East and Africa. It evaluates the impact of AI adoption on the CNS biomarkers industry and market dynamics, including drivers, challenges and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major market participants and their offerings.

Global revenue ($ million) for the base year of 2024, estimates for 2025 and data for the forecast period 2025 through 2030 are also part of the report.

Report Includes

• 141 data tables and 44 additional tables
• An up-to-date overview and analysis of the global market for central nervous system (CNS) biomarkers
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of CAGRs through 2030
• Analysis of market opportunities with a holistic review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro-environmental factors prevailing in the market
• Explanation of market drivers, restraints and other forces impacting the global market
• Discussion of CNS disease segments, prevalence and gaps in treatment for Alzheimer's disease, depression, Parkinson's disease, multiple sclerosis, etc.
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the practices of leading companies
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
• Profiles of the leading global companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott and Bio-Rad Laboratories Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Outlook
• Analysis of Macroeconomic Factors
• Impact of U.S. Tariffs on the Market
• Impact of the Ukraine-Russia War
• Global Economic Stability and Supply Chains
• Public and Private R&D Investment
• Healthcare Expenditure and Economic Growth
• Aging Population and Disease Burden
• Porter's Five Forces Analysis
• Bargaining Power of Buyers: Moderate to High
• Bargaining Power of Suppliers: High
• Potential for New Entrants: Moderate to Low
• Threat of Substitute: Moderate
• Competition in the Industry: High

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Prevalence of Neurological Disorders
• Advances in Diagnostic Technologies and Research
• Focus on Early Detection and Personalized Medicine
• Market Restraints
• High Cost of Advanced Diagnostic Assays
• Regulatory and Validation Challenges
• Limited Awareness and Adoption Among Healthcare Providers
• Market Opportunities
• Growth in Neurodegenerative Disease Research
• Expansion of Early Diagnosis and Screening Programs
• Integration with Personalized Medicine

Chapter 4 Regulatory Landscape

• Regulatory Framework
• U.S.
• Europe
• India
• Australia
• Japan

Chapter 5 Emerging Technologies and Patent Analysis

• Overview
• Emerging Technologies
• High-Resolution Mass Spectrometry
• Next-Generation Sequencing
• Multiplexed Immunoassays
• Single-Cell RNA Sequencing
• Patent Analysis
• Key Takeaways
• Patents by Year
• Patents by Leading Jurisdiction
• Patents by Applicants

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global CNS Biomarkers Market, by Disease
• Key Takeaways
• Alzheimer's Disease
• MS, ALS and FTD
• Parkinson's Disease
• Others
• Global CNS Biomarkers Market, by Application
• Key Takeaways
• Drug Discovery and Development
• Clinical Diagnostics
• Personalized Medicine
• Global CNS Biomarkers Market, by Technology
• Key Takeaways
• Proteomics
• Molecular Imaging
• Genomics
• Global CNS Biomarkers Market, by Biomarker Type
• Key Takeaways
• Amyloid-Beta
• Tau Protein
• Others
• Geographic Breakdown
• Global CNS Biomarkers Market, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Industry Structure
• Company Market Share Analysis
• Strategic Analysis

Chapter 8 Sustainability in the CNS Biomarkers Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives in the CNS Biomarkers Industry
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Abbreviations
• Company Profiles
• ABBOTT
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• C2N DIAGNOSTICS
• F. HOFFMANN-LA ROCHE LTD.
• FUJIREBIO
• LABCORP
• LILLY USA LLC.
• MERCK KGAA
• QUANTERIX
• QUEST DIAGNOSTICS INC.
• REVVITY
• SIEMENS HEALTHINEERS AG
• SYSMEX CORP.
• THERMO FISHER SCIENTIFIC INC.
• Emerging Start-ups/Market Disruptors